Compare Sana Biotechnology Inc (SANA) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $947.48M), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.73. Which is the better fit depends on your goals.
| SANA | VTIP | |
|---|---|---|
Market Cap | $947.48M | — |
Sector | Health | — |
52-Week High | $5.92 | $50.75 |
52-Week Low | $2.68 | $49.39 |
Enterprise Value | $860.73M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
VTIP (Vanguard Short-Term Inflation-Protected Securities ETF) trades at $49.75 with minimal daily movement (+0.04%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The fund focuses on short-duration TIPS to hedge inflation with reduced interest-rate sensitivity. Recent news highlights its role as a low-cost inflation hedge amid persistent above-target inflation and multi-decade high real yields on long-term TIPS.
Outlook: VTIP offers a defensive allocation for inflation protection, but bearish technicals and flat performance (4% gain since June 2025 per ETF Trends) limit near-term upside. Risks include interest-rate volatility and inflation trajectory shifts. Institutional interest grew with 55 North Private Wealth increasing holdings by 12.2% in Q2 2026 (Defense World, Aug 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
